pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-371b |
Genomic Coordinates | chr19: 53787677 - 53787742 |
Description | Homo sapiens miR-371b stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-371b-3p | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sequence | 43| AAGUGCCCCCACAGUUUGAGUGC |65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | AREL1 | ||||||||||||||||||||
Synonyms | FIEL1, KIAA0317 | ||||||||||||||||||||
Description | apoptosis resistant E3 ubiquitin protein ligase 1 | ||||||||||||||||||||
Transcript | NM_001039479 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on AREL1 | |||||||||||||||||||||
3'UTR of AREL1 (miRNA target sites are highlighted) |
>AREL1|NM_001039479|3'UTR 1 CCACTCTCCTGTCATCCAGTTGGCTCCCATGCTCTCTGGAGCTTCTGGGCGCAAGTTACAGACATCATAACCACTGATCC 81 TAACACACATAACCATCAGCCAGAAGATGCCGCATGCTCCCCTGTGTCTGGAGGATTTTGTCACCTACAAGCCTTGTCTT 161 TACCTCACCTGCTCCCTGCCCATATCTACCACAGGCCACTTTGGCATGGTATGTAAGCTGAGCTCTTCATTCTGTCATGA 241 GAAGAGGACCATGCTGCTATCATTTATTTGGTCCTTTGAAGATCTCAGTAGCTGAGGGAGATGGCACACGGGGCTCAGCC 321 CTGTTGGGAAACTGGTGTGGAGACCCTTAAATCCACACTGTGCTCCAAAACTCCCTCTGCTGATACTCCTTGGAGACACC 401 CTCTTTGGCCCTCACTACTTGACCAGACTGGTACTTGAGTCCTTCTCATGGGTGGGGTGATTGCCTCTTCTCATCAGGAG 481 CCAGGAGAGAGGGGGACAGATAGGAGGTGGCCCATAGGAGCAGTCCCGCTGCACAATGGTAGGCATAGGCCATGGCACTG 561 GACTGCCTCTAAGGACTGCTAAAAAGAATATTTTTTTGTGGTGTCAGAACTGGAAAAAGCACTTTCCCTTCGGGCATTTC 641 TGGAAATGATTATTAATCCACAAAGAAGAACTCTGTAAGCTTTTTCTTGAATTGTAGCCAGTGAGAAAAGCAGATAGACT 721 GAAGAATATGAAGGATAGCTGAGCTGTAGCCTCCAGAGTGGGGCATGCCTAGGCATATGGCTGGCTTGGAGACTACTGAT 801 GCTTTTCCCTGAGTTTGTTATTGGCACTGAAGTATGGCCGGCTTGGGCCACTGACTTCCCCATTATGTAGTCTGCTAAAA 881 GCTGGGGATCCTTTAGCATTCTACTGAAGAAAATTTTGTAGCAAAAGATTAGAACAGTAAGAATAGTATGCCAGCAATCC 961 CTGATTCTCTCTCTGCTTGGTGTTCTCTGGCAGCACTAAGACAAAGGAACAGGGACTAGGAGTTTACGTGCTTATCACAG 1041 GTCCTTGGCGTCAGGACACTAGGGATGAACATGGAGGTGATATGTTACACAGTAAACACCTGCCAACCCCTGTACTCCCC 1121 TTTGCTCCATCAGTTATCAGGAAGGAGAACTAAGGAGGGAGGAAGCTTATTAGGTTCACTGTTGAATGATGATTGAAGAG 1201 TACCTGCTGCTGTATCTTGGAAGATGACAACATCCTTTTTCATTACTGTTTGATTGAAAATAATTTCAAGATTCAAAATC 1281 TCATTGACTTCCCAAATTTGTGTTTTTAAGAAGGCTTTGCTGCAAGCTACCATTCCCAATGGGGCAGTCAACTCTGAGAA 1361 TATTACAAGCCATCTTTATTGCCAAAACCAGCAAGTACACAGAGTCCTGAAACAAGGCAGGACTTTGGCAATGCCTTGGC 1441 CTCCTGGAAGCATGTCTGAGCCCTCCTGTTCGCAGGGATCATGAGGAACAAGCCCTCCTGAGCTGCTACAGTTCCTGCCT 1521 GACCTCAGTCTTTCGCAGTCATCATTTGTCCTTTCTTGGCACATGGGTGCTGACCTCACTCATCCTTGGGGTCCGGGATC 1601 CAGCATCAGGGTCTCTATACCCCAGGATCCTCCATGCCACATGGTCACTGCTCTCCTCAGGGACCAGGACAAGGTGCTGC 1681 TGCTTGCCCAAATGTTTTCCCATGGGATATGTACCGGAAGGTTTATCACCACCCTGGGAAACATAATGCTGCCCCTTGGG 1761 CCCAGAAAGGGGTTTCCAGCTGGGGGCACGTGGACTGGTTCTGCTGTTTTTGGCAGTCGCTTTTCTGAATTCTCCCCTCC 1841 GGCAGCCTTCCAGAGACTGATCCTGGAGATTGAGTTGATTGTCTTGGCTAGACCTGTCATTTTAAGCTCTAGTCATAGCA 1921 CTTTTTCAGAGCATCTTAGGCACCATTGCAACCCAACCAGGGAAGCTGCATCCCTGTGGTGGTCCTTAGGCACCAGTCTT 2001 TGTTAAACAAAACCCTTTGGCACTATTGTGGTTTTCTATTCTCTGTCTGAACTCTATTCAAAAGTATCTTTGCTCTCTTG 2081 GGCCTTTTCTTTTACTGTTTTGTTTTTTTTTTTTCTAATCCTGCTTTCATACTAGCCAGTGTGGGGAAAAGGTACAATAT 2161 GTCAAAGAGATGAGAGAGTGTTATTTCTTGGGCAATTTTCTATTAGTGTTTCTTATTTTGGCCAGTTCTTTTATTTATGT 2241 CCTTGTGACCCAGGTACTTGGGGGGCCAGCTACCCTTCTGGCCTTTTAGCGTCTTTGAAGGAGACCAGACATGAGTGAAT 2321 ACCTAGGAGAGTGTCAGCATGTTTCTGGAAAATTGGCAGAGACCAAGCCCTGCTGCAGATTCGTCAGGCCAGGTGAAAGG 2401 GCCAGGCAGTTGCAGCTGATGATGTAAATATTTTGTACAGTAGATAAATAAATGTTTAAAAGAACTAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 9870.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
CLIP-seq Support 1 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000356357.4 | 3UTR | UUAAACAAAACCCUUUGGCACUAUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
42 hsa-miR-371b-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT055410 | SHOC2 | SHOC2, leucine rich repeat scaffold protein | 2 | 6 | ||||||||
MIRT065883 | GDF11 | growth differentiation factor 11 | 2 | 2 | ||||||||
MIRT183507 | BTG2 | BTG anti-proliferation factor 2 | 2 | 2 | ||||||||
MIRT277106 | CDCA8 | cell division cycle associated 8 | 2 | 2 | ||||||||
MIRT300592 | CRKL | CRK like proto-oncogene, adaptor protein | 2 | 2 | ||||||||
MIRT441361 | ZNF75A | zinc finger protein 75a | 2 | 2 | ||||||||
MIRT442692 | COX15 | COX15, cytochrome c oxidase assembly homolog | 2 | 2 | ||||||||
MIRT443388 | CHML | CHM like, Rab escort protein 2 | 2 | 2 | ||||||||
MIRT443571 | EVX2 | even-skipped homeobox 2 | 2 | 2 | ||||||||
MIRT443671 | FLT1 | fms related tyrosine kinase 1 | 2 | 2 | ||||||||
MIRT465524 | PRICKLE4 | prickle planar cell polarity protein 4 | 2 | 2 | ||||||||
MIRT492169 | STAT3 | signal transducer and activator of transcription 3 | 2 | 2 | ||||||||
MIRT496992 | TMEM231 | transmembrane protein 231 | 2 | 2 | ||||||||
MIRT509012 | FBXO6 | F-box protein 6 | 2 | 2 | ||||||||
MIRT509766 | NCAPD2 | non-SMC condensin I complex subunit D2 | 2 | 2 | ||||||||
MIRT514033 | BNIP2 | BCL2 interacting protein 2 | 2 | 2 | ||||||||
MIRT524995 | AFF1 | AF4/FMR2 family member 1 | 2 | 10 | ||||||||
MIRT529899 | C1orf64 | steroid receptor associated and regulated protein | 2 | 2 | ||||||||
MIRT530045 | SMC1A | structural maintenance of chromosomes 1A | 2 | 2 | ||||||||
MIRT534479 | SAR1B | secretion associated Ras related GTPase 1B | 2 | 2 | ||||||||
MIRT535065 | PPP2R5D | protein phosphatase 2 regulatory subunit B'delta | 2 | 4 | ||||||||
MIRT539151 | AREL1 | apoptosis resistant E3 ubiquitin protein ligase 1 | 2 | 2 | ||||||||
MIRT540937 | OIP5 | Opa interacting protein 5 | 2 | 2 | ||||||||
MIRT546360 | SYNM | synemin | 2 | 2 | ||||||||
MIRT553436 | TPM3 | tropomyosin 3 | 2 | 2 | ||||||||
MIRT556278 | MAPK1 | mitogen-activated protein kinase 1 | 2 | 2 | ||||||||
MIRT564092 | NSA2 | NSA2, ribosome biogenesis homolog | 2 | 2 | ||||||||
MIRT568376 | ATXN1 | ataxin 1 | 2 | 2 | ||||||||
MIRT572255 | ANKRD52 | ankyrin repeat domain 52 | 2 | 2 | ||||||||
MIRT572453 | TRIM10 | tripartite motif containing 10 | 2 | 2 | ||||||||
MIRT610741 | NUDT16 | nudix hydrolase 16 | 2 | 4 | ||||||||
MIRT622754 | PHACTR2 | phosphatase and actin regulator 2 | 2 | 2 | ||||||||
MIRT627220 | ZC3H12B | zinc finger CCCH-type containing 12B | 2 | 2 | ||||||||
MIRT629555 | SPN | sialophorin | 2 | 2 | ||||||||
MIRT640288 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | 2 | 2 | ||||||||
MIRT651922 | UEVLD | UEV and lactate/malate dehyrogenase domains | 2 | 2 | ||||||||
MIRT684290 | CDK9 | cyclin dependent kinase 9 | 2 | 2 | ||||||||
MIRT700230 | REL | REL proto-oncogene, NF-kB subunit | 2 | 2 | ||||||||
MIRT702748 | IGFBP3 | insulin like growth factor binding protein 3 | 2 | 2 | ||||||||
MIRT711110 | TBC1D21 | TBC1 domain family member 21 | 2 | 2 | ||||||||
MIRT716402 | SEPT5 | septin 5 | 2 | 2 | ||||||||
MIRT723677 | CTC1 | CST telomere replication complex component 1 | 2 | 2 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|